STAT June 20, 2024
Angus Chen

When they work, immunotherapy drugs called checkpoint inhibitors can shrink cancers and, in some cases, eradicate tumors altogether. These drugs, which include Keytruda and Opdivo, are prescribed to hundreds of thousands of patients a year for dozens of different kinds of cancer — but they only work for a minority of them. Most patients ultimately end up progressing or relapsing.

In two separate clinical trials published in Science on Thursday, researchers found that adding a drug called a JAK inhibitor created an unexpected synergy with checkpoint inhibitor therapy. The combination helped a majority of patients respond to the immunotherapy and, in one...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma, Pharma / Biotech, Trends
What 14 pharmacy chiefs will prioritize for the next 6 months
What Amazon has done in the first half of 2024
Aiming to Top Amgen in Gout, Startup GRObio Gets $60M to Enter the Clinic
These health care professionals may be secret weapon against hypertension, study says
Ozempic Shortages Raise Questions About Prioritizing Access For Diabetics

Share This Article